AI assistant
Sending…
VYNE Therapeutics Inc. — Director's Dealing 2021
Jan 5, 2021
35290_dirs_2021-01-05_490f5d92-2735-49c4-ace7-2f11cbc66b46.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2020-12-31
Reporting Person: Wiley Matthew T. (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Common Stock | F | 1541 | $1.58 | Disposed | 357181 | Direct |
Footnotes
F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
More from VYNE Therapeutics Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Mar 31
Annual Report
2026
Feb 27
Regulatory Filings
2026
Jan 30
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5